Tags

Type your tag names separated by a space and hit enter

Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients.
J Oncol Pharm Pract. 2017 Jul; 23(5):344-349.JO

Abstract

Objective The objective of this study was to compare clinical outcomes in children undergoing hematopoietic cell transplantation who received levetiracetam versus those who received phenytoin for the prevention of busulfan-induced seizures. Methods This study was an IRB-approved, single-center, retrospective analysis of pediatric patients receiving intravenous busulfan for hematopoietic cell transplantation conditioning from January 2009 to July 2014. The primary study endpoint was the incidence of seizure during busulfan administration (day -8 to 0). Key transplant related-outcomes were also collected, including the incidence of graft rejection, sinusoidal obstruction syndrome, relapse, and death. Results A total of 20 patients met criteria for inclusion in the study. The population was heterogeneous with regard to the indication for hematopoietic cell transplantation, donor type, stem cell source, and conditioning regimen. Nine patients (45%) received levetiracetam and 11 (55%) received phenytoin for seizure prophylaxis. No seizures or graft rejections were observed in the study population. One relapse, one case of sinusoidal obstruction syndrome, and two deaths occurred in the levetiracetam group, while no relapses, two cases of sinusoidal obstruction syndrome, and one death occurred in the phenytoin group. Conclusion These data suggest similar safety and effectiveness between levetiracetam and phenytoin for the prevention of busulfan-induced seizures in a small, heterogeneous pediatric hematopoietic cell transplantation population.

Authors+Show Affiliations

1 Department of Pharmacy Services, Oregon Health & Science University, Portland, USA.2 Department of Pharmacy and Department of Pharmaceutics, University of Washington, Seattle, USA. 3 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, USA.

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

27208016

Citation

Floeter, Abby E., and Jeannine S. McCune. "Levetiracetam for the Prevention of Busulfan-induced Seizures in Pediatric Hematopoietic Cell Transplantation Recipients." Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, vol. 23, no. 5, 2017, pp. 344-349.
Floeter AE, McCune JS. Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. J Oncol Pharm Pract. 2017;23(5):344-349.
Floeter, A. E., & McCune, J. S. (2017). Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, 23(5), 344-349. https://doi.org/10.1177/1078155216651128
Floeter AE, McCune JS. Levetiracetam for the Prevention of Busulfan-induced Seizures in Pediatric Hematopoietic Cell Transplantation Recipients. J Oncol Pharm Pract. 2017;23(5):344-349. PubMed PMID: 27208016.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. AU - Floeter,Abby E, AU - McCune,Jeannine S, Y1 - 2016/05/20/ PY - 2016/5/22/pubmed PY - 2018/7/13/medline PY - 2016/5/22/entrez KW - Antiepileptic drug KW - busulfan KW - levetiracetam KW - phenytoin KW - seizures SP - 344 EP - 349 JF - Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners JO - J Oncol Pharm Pract VL - 23 IS - 5 N2 - Objective The objective of this study was to compare clinical outcomes in children undergoing hematopoietic cell transplantation who received levetiracetam versus those who received phenytoin for the prevention of busulfan-induced seizures. Methods This study was an IRB-approved, single-center, retrospective analysis of pediatric patients receiving intravenous busulfan for hematopoietic cell transplantation conditioning from January 2009 to July 2014. The primary study endpoint was the incidence of seizure during busulfan administration (day -8 to 0). Key transplant related-outcomes were also collected, including the incidence of graft rejection, sinusoidal obstruction syndrome, relapse, and death. Results A total of 20 patients met criteria for inclusion in the study. The population was heterogeneous with regard to the indication for hematopoietic cell transplantation, donor type, stem cell source, and conditioning regimen. Nine patients (45%) received levetiracetam and 11 (55%) received phenytoin for seizure prophylaxis. No seizures or graft rejections were observed in the study population. One relapse, one case of sinusoidal obstruction syndrome, and two deaths occurred in the levetiracetam group, while no relapses, two cases of sinusoidal obstruction syndrome, and one death occurred in the phenytoin group. Conclusion These data suggest similar safety and effectiveness between levetiracetam and phenytoin for the prevention of busulfan-induced seizures in a small, heterogeneous pediatric hematopoietic cell transplantation population. SN - 1477-092X UR - https://www.unboundmedicine.com/medline/citation/27208016/Levetiracetam_for_the_prevention_of_busulfan_induced_seizures_in_pediatric_hematopoietic_cell_transplantation_recipients_ L2 - https://journals.sagepub.com/doi/10.1177/1078155216651128?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -